Montelukast Junior Ratiopharm (Montelukast Sodium)

The drug blocks the cysteinyl leukotriene receptor CysLT1, preventing leukotriene D4 and related mediators from triggering bronchoconstriction, mucus production, and inflammation in the airways, which helps keep breathing easier.

The specific dose is determined by the prescribing clinician based on the patient’s age, weight, and clinical condition. Pediatric dosing guidelines exist, but the exact regimen should be set by a qualified healthcare professional.

Safety data for Montelukast in pregnancy and lactation are limited. It should only be used if the potential benefit outweighs any possible risk, and the decision must be made in consultation with a healthcare provider.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting beta‑agonists. It is particularly useful for patients who need additional control of allergic components or who prefer a tablet over inhalation, though it is generally used as adjunct therapy rather than a sole replacement for inhaled steroids.

Store the tablets at room temperature, below 25 °C, in the original blister pack. Keep them away from moisture, direct sunlight and excessive heat to maintain product stability.

The medication is taken orally as a tablet. It should be swallowed whole with a glass of water, preferably at the same time each day, and can be taken with or without food as directed by the prescriber.

Serious adverse events include severe allergic reactions such as rash or angioedema, neuropsychiatric effects like depression or suicidal thoughts, and liver enzyme abnormalities. Patients should seek immediate medical attention if any of these symptoms develop.

Individuals with known hypersensitivity to montelukast sodium or any of the tablet’s excipients should avoid the product. Caution is also advised for patients with severe hepatic impairment, and the drug is not recommended for use in children under the approved age range without specialist guidance.